相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)
Alberto Fernandez et al.
CLINICAL ENDOCRINOLOGY (2010)
Mortality in Patients with Pituitary Disease
Mark Sherlock et al.
ENDOCRINE REVIEWS (2010)
Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
S. Petersenn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study
Jan-Hendrik Buhk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Long-term experience of pegvisomant therapy as a treatment for acromegaly
C. E. Higham et al.
CLINICAL ENDOCRINOLOGY (2009)
Valvular heart disease and the use of cabergoline for the treatment of prolactinoma
Neil Herring et al.
CLINICAL ENDOCRINOLOGY (2009)
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
Peter J. Trainer et al.
CLINICAL ENDOCRINOLOGY (2009)
Subcutaneous lipoatrophy induced by long-term pegvisomant administration
Cannavo Salvatore et al.
CLINICAL ENDOCRINOLOGY (2009)
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
S. J. C. M. M. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
ACROSTUDY: the first 5 years
Peter J. Trainer
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues
M. Sherlock et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy
E. Ghigo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2009)
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
Diego Ferone et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2009)
Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide
Raquel S. Jallad et al.
NEUROENDOCRINOLOGY (2009)
Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment
Ana Paula M. Casarini et al.
PITUITARY (2009)
High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels
H. J. Schneider et al.
CLINICAL ENDOCRINOLOGY (2008)
Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly
Peter Kamenicky et al.
ENDOCRINOLOGY (2008)
Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register
S. Petersenn et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
V. J. Moyes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials
Camilo Jimenez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
Robert D. Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Lipodystrophy in patients with acromegaly receiving pegvisomant
Vivien S. Bonert et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Correlation of in Vitro and in Vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
Diego Ferone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Sven M. Carlsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Growth hormone response during oral glucose tolerance test:: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index
Ayman M. Arafat et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas
A. S. Aveanu et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation
Becky L. Conway-Campbell et al.
MOLECULAR ENDOCRINOLOGY (2008)
Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR):: an open, multicentre longitudinal study
C. L. Ronchi et al.
CLINICAL ENDOCRINOLOGY (2007)
Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy
Lawrence A. Frohman et al.
PITUITARY (2007)
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa
Jean Christophe Maiza et al.
CLINICAL ENDOCRINOLOGY (2007)
A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors
Sylvia L. Asa et al.
CANCER RESEARCH (2007)
Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice
A. Pokrajac et al.
CLINICAL ENDOCRINOLOGY (2007)
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient
Eugenia Resmini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3
A. P. M. Casarini et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2006)
Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg:: a phase III trial
T. Lucas et al.
CLINICAL ENDOCRINOLOGY (2006)
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Felipe F. Casanueva et al.
CLINICAL ENDOCRINOLOGY (2006)
Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation
AA van der Klaauw et al.
GROWTH HORMONE & IGF RESEARCH (2006)
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Managing acromegaly with somatostatin analogs - A team approach
DM Cook et al.
ENDOCRINOLOGIST (2006)
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas
Alexandru Saveanu et al.
NEUROENDOCRINOLOGY (2006)
Postoperative evaluation of patients with acromegaly: Clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
RA Feelders et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Pharmacokinetic profile of lanreotide Autogel® in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days
M Bronstein et al.
CLINICAL ENDOCRINOLOGY (2005)
The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly
S Bhayana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant
AL Barkan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A nationwide survey of mortality in acromegaly
R Kauppinen-Mäkelin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
P Jaquet et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
J Feenstra et al.
LANCET (2005)
Presurgical octreotide treatment in acromegaly:: no improvement of final growth hormone (GH) concentration and pituitary function.: A long-term case-control study
U Plöckinger et al.
ACTA NEUROCHIRURGICA (2005)
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
D Selvarajah et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly
N Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2005)
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly
J Ayuk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy
J Ayuk et al.
CLINICAL ENDOCRINOLOGY (2004)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
J van der Hoek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Significance of abnormal nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
O Alexopoulou et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly
HE Turner et al.
CLINICAL ENDOCRINOLOGY (2004)
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
R Cozzi et al.
CLINICAL ENDOCRINOLOGY (2004)
Cost-of-illness study in acromegalic patients in Italy
G Didoni et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Increased prevalence of regurgitant valvular heart disease in acromegaly
AM Pereira et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results?
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Sandostatin LAR in acromegaly:: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval
NR Biermasz et al.
CLINICAL ENDOCRINOLOGY (2003)
Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly
C Beauregard et al.
CLINICAL ENDOCRINOLOGY (2003)
Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size
JS Bevan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
JJ Kopchick et al.
ENDOCRINE REVIEWS (2002)
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly
J Ayuk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
